262 related articles for article (PubMed ID: 31549214)
1. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.
Osborne N; Sundseth R; Burks J; Cao H; Liu X; Kroemer AH; Sutton L; Cato A; Smith JP
Cancer Immunol Immunother; 2019 Oct; 68(10):1635-1648. PubMed ID: 31549214
[TBL] [Abstract][Full Text] [Related]
2. Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.
Osborne N; Sundseth R; Gay MD; Cao H; Tucker RD; Nadella S; Wang S; Liu X; Kroemer A; Sutton L; Cato A; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2019 Nov; 317(5):G682-G693. PubMed ID: 31433212
[TBL] [Abstract][Full Text] [Related]
3. Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer.
Smith JP; Cao H; Chen W; Mahmood K; Phillips T; Sutton L; Cato A
Front Oncol; 2021; 11():788875. PubMed ID: 34926305
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
5. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
6. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
[TBL] [Abstract][Full Text] [Related]
9. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
Karyampudi L; Lamichhane P; Scheid AD; Kalli KR; Shreeder B; Krempski JW; Behrens MD; Knutson KL
Cancer Res; 2014 Jun; 74(11):2974-85. PubMed ID: 24728077
[TBL] [Abstract][Full Text] [Related]
11. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
12. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
[TBL] [Abstract][Full Text] [Related]
13. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model.
Smith JP; Cao H; Chen W; Kallakury B; Phillips T; Sutton L; Cato A
Cancer Prev Res (Phila); 2021 Oct; 14(10):933-944. PubMed ID: 34429319
[TBL] [Abstract][Full Text] [Related]
17. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
18. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
19. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
20. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Martínez-Usatorre A; Donda A; Zehn D; Romero P
J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
